ArticleScientific reports2025
Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages in the tumor microenvironment.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiotherapy as a partner for immunotherapy in pancreatic cancer: current landscape and future directions.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the most intractable cancer, demonstrating abundant stroma in the tumor microenvironment (TME). Previously, we reported that CXC chemokines contributed to the progression of PDAC through tumor-stromal interaction. Since CC chemokines were also highly expressed in the TME, we hypothesized that the CC chemokine signaling promotes PDAC progression. CC chemokine receptor 2 (CCR2) was primarily expressed in macrophages in the murine PDAC tissues, therefore, we investigated the role of CCR2 in the interaction between macrophages and PDAC cells. Macrophages significantly induced PDAC cell invasion in vitro, whereas, the induction was canceled by Ccr2-knockout (KO) macrophages. CXC chemokines, differentially expressed between wild-type and Ccr2 KO macrophages, contributed to the PDAC invasion. Systemic Ccr2 KO significantly prolonged the survival of autochthonous PDAC mice, demonstrating a shift of macrophage composition, decrease of Arginase-1+ and increase of iNOS+ macrophages, and decrease of PDAC microinvasion, as well as increase of PDAC apoptosis. PDAC cells stimulated by Ccr2 KO macrophages showed activated interferon-α (Ifn-α)-STAT1 signaling, while Ccr2 KO upregulated Ifn-α expression, thereby directly inducing PDAC cell apoptosis. These results elucidated the pivotal role of CCR2 in PDAC progression and inhibition through the interaction of macrophages and PDAC cells in the TME.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.